Author

Erin Ahn

Observed name: E Ahn

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5071483113

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance

2020 · Morton Coleman, David Jacob Andorsky, et al. · Blood · 5

Patients With Relapsed/refractory Marginal Zone Lymphoma in the Magnify Phase 3b Interim Analysis of Induction R2 Followed by Maintenance

2021 · M Coleman, DJ Andorsky, et al. · Hematology Transfusion and Cell Therapy · 2

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

2020 · Frederick Lansigan, David Jacob Andorsky, et al. · Blood · 2

m 6a-Son-CCL5 Axis Controls HSC Fate and Inflammation

2023 · Hanzhi Luo, Mariela Cortés-López, et al. · Blood

Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

2023 · Shazia Nakhoda, Tamarrah Sklarz, et al. · Blood

Subgroup Analyses of Elderly Patients Aged 70 Years in Magnify: a Phase 3b Interim Analysis of Induction R2 Followed by Maintenance in Relapsed/refractory Indolent Non-hodgkin Lymphoma

2021 · F Lansigan, DJ Andorsky, et al. · Hematology Transfusion and Cell Therapy

Works count: 6

Citation count: 9

H-index: 2

I10-index: